A Randomized, Double-Blind, Study to Explore the Efficacy and Safety of RE-021 in Focal Segmental Glomerulosclerosis (FONT-3)
This study is not yet open for participant recruitment.
Verified July 2012 by Retrophin, LLC.
Information provided by (Responsible Party):
First received: June 4, 2012
Last updated: July 24, 2012
Last verified: July 2012
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is not yet open for participant recruitment.|
|Estimated Study Completion Date:||March 2013|
|Estimated Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|